medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2014, Número 1

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2014; 12 (1)


Cáncer de piel en pacientes con trasplante de órgano sólido

Arellano MI, García C, Baños SC

Idioma: Español
Referencias bibliográficas: 59
Paginas: 58-71
Archivo PDF: 300.89 Kb.


RESUMEN

En los últimos años se ha incrementado el número de trasplantes de órgano sólido (TOS), así como la supervivencia de esos pacientes. Sin embargo, el uso de inmunosupresores para evitar rechazos aumenta el riesgo de desarrollar cánceres de piel y de ellos, el más común es el carcinoma cutáneo no melanoma (CCNM), que suele tener un comportamiento más agresivo y mayor morbimortalidad que los tumores equivalentes observados en la población general. Dado que el dermatólogo desempeña un papel fundamental en la prevención y el diagnóstico temprano de estas entidades, el presente artículo pretende ofrecer una actualización en el tema.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Greenberg JN. Zwald FO. “Management of skin cancer in solid-organ trasplant recipients: A multidisciplinary approach”. Dermatol Clin. 2011. 29: 231-241.

  2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. “Improved graft survival after renal trasplantation in the United States, 1988 to 1996”. N Engl J Med. 2000; 342: 605-612.

  3. Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. “Twelve years’ experience with national sharing of HLA-matched cadaveric kidneys for trasplantation”. N Engl J Med. 2000; 343: 1078-1084.

  4. Edwards NM, Rajasinghe HA, John R, Chen JM, Itescu S, Mancini DM. “Cardiac trasplantation in over 1000 patients: a single institution experience from Columbia University”. Clin Transpl. 1999: 249-261.

  5. Nguyen TH, Ho DQ. “Nonmelanoma skin cancer”. Curr Treat Options Oncol. 2002; 3: 193-203.

  6. Stasko T, Brown MD, Carucci JA, Euvrard S, Johnson T, Sengelmann RD. “Guidelines for management of squamous cell carcinoma in organ trasplant recipients”. Dermatol Surg. 2004; 30: 642-650.

  7. Zwald FO, Brown M. “Skin cancer in solid organ trasplant recipients: Advances in therapy and management. Part I Epidemiology of skin cancer in solid organ trasplant recipients”. J Am Acad Dermatol. 2011; 65: 253-261.

  8. Ho WL, Murphy GM. “Update on the pathogenesis of post-trasplant skin cancer in renal trasplant recipients”. Br J Dermatol. 2008; 158: 217- 224.

  9. Euvrard S, Kanitakis J, Cochat P, Claudy A. “Skin cancers following pediatric organ trasplantation”. Dermatol Surg. 2004; 30: 616-621.

  10. Tessari G, Girolomoni G. “Nonmelanoma skin cancer in solid organ trasplant recipients: update on epidemiology, risk factors, and management”. Dermatol Surg. 2012; 38: 1622-1630.

  11. Bangash HK, Colegio OR. “Management of non-melanoma skin cancer in immunocompromised solid organ trasplant recipients”. Curr Treat Options Oncol. 2012; 13: 354-376.

  12. Lewis KG, Jellinek N, Robinson-Bostom L. “Skin cancer after trasplantation: a Guide for the general Surgeon”. Surg Clin N Am. 2006; 86: 1257-1276.

  13. Tessari G, Naldi L, Boschiero L, Nacchia F, Fior F, Forni A et al. “Incidence and Clinical Predictors of a Subsequent Nonmelanoma Skin Cancer in Solid Organ Trasplant Recipients With a First Nonmelanoma Skin Cancer. A Multicenter Cohort Study”. Arch Dermatol. 2010; 146: 294-299.

  14. Berg D, Otley CC. “Skin cancer in organ trasplant recipients: Epidemiology, pathogenesis, and management”. J Am Acad Dermatol. 2002; 47: 1-17.

  15. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. “Incidence and clinical course of de-novo malignancies in renal allograft recipients”. Eur J Surg Oncol. 2001; 27: 409-413.

  16. Leblanc KG, Hugues MP, Sheehan DJ. “The role of sirulimus in the prevention of cutaneous squamous cell Carcinoma in organ trasplant recipients”. Dermatol Surg. 2011; 37: 744-740.

  17. Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. “Skin cancer in Australian heart trasplant recipients”. J Am Acad Dermatol. 1999; 40: 27-34.

  18. Sheil AG. “Patterns of malignancies following renal trasplantation. Trasplant Proc”. 1999; 31: 1263-1265

  19. Martinez JC, Otley CC, Stasko T, Euvrard S, Brown C, Schanbacher CF, et al. “Trasplant-Skin Cancer Collaborative. Defining the clinical course of metastatic skin cancer in organ trasplant recipients: a multicenter collaborative study”. Arch Dermatol. 2003; 139: 301-306.

  20. Otley CC. “Pretrasplantation dermatologic screening and prophylaxis”. Cancer Treat Res. 2009; 146: 391-404.

  21. Mougel F, Kanitakis J, Faure M, Euvrard S. “Basosquamous cell carcinoma in organ trasplant patients: a clinicopathologic study”. J Am Acad Dermatol. 2012; 66: 151-157.

  22. Kovacha BT, Staskob T. “Skin cancer after trasplantation”. Trasplantation Reviews. 2009; 23: 178–189.

  23. Penn I. “Malignant melanoma in organ allograft recipients”. Trasplantation. 1996; 61: 274-278.

  24. Dinh QQ, Chong AH. “Melanoma in organ trasplant recipients: The old enemy finds a new battleground”. Australas J Dermatol. 2007; 48; 199-207.

  25. Muñoz P, Alvarez P, De Ory F, Pozo F, Rivera M, Bouza E. “Incidence and Clinical Characteristics of Kaposi Sarcoma After Solid Organ Trasplantation in Spain: Importance of Seroconversion Against HHV- 8”. Medicine. 2002; 81: 293-304.

  26. Boeckle E, Boesmueller C, Wiesmayr S, Mark W, Rieger M, Tabarelli D, et al. “Kaposi sarcoma in solid organ trasplant recipients: a single center report”. Trasplant Proc. 2005; 37: 1905-1909.

  27. Stallone G, Infante B, Grandaliano J, Schena F, Gesualdo L. “Kaposi`s sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression”. Trasplat Int. 2008. 21: 825-832.

  28. Méndez JC, Paya CV. “Kaposi`s Sarcoma and trasplantation”. Herpes. 2000; 7: 18-23.

  29. Kanitakis J, Euvrard S, Chouvet B, Butnaru AC, Claudy A. “Merkel cell carcinoma in organ-trasplant recipients: report of two cases with unusual histological features and literature review”. J Cutan Pathol. 2006; 33: 686-694.

  30. Nelson BP, Wolniak KL, Evens A, Chenn A, Maddalozzo J, Proytcheva M. “Early posttrasplant lymphoproliferative disease: clinicopathologic features and correlation with mTOR signaling pathway activation”. Am J Clin Pathol. 2012; 138: 568-578.

  31. Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ. “Presentation and early detection of post-trasplant lymphoproliferative disorder after solid organ trasplantation”. Trasplant Int. 2007: 20: 207-218.

  32. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A. Gordon LI. “Post-trasplantation lymphoproliferative disorders: diagnosis, prognosis, and current aproaches to therapy”. Curr Oncol Rep. 2010; 12: 383- 394.

  33. Snavely NR, Sonabend M, Rosen T. “ Posttrasplant Epstein-Barr virus related lymphoproliferative disorder with a primary cutaneous presentation” Dermatol Online J. 2007; 13: 7.

  34. Robbins HY, Arcasoy SM. “Malignancies following lung trasplantation”. Clin Chest Med. 2011; 32: 343-355.

  35. Rama I, Grinyó JM. “Malignancy after renal trasplantation: the role of inmmunosuppression”. Nat. Rev. Nephrol. 2010; 6: 511-519.

  36. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. “Risk of neoplasia in renal trasplant patients”. Lancet. 1995; 346: 403-406.

  37. Hofbauer GF, Bouwes JN, Euvrard S. “Organ trasplantation and skin cancer: basic problems and new perspectives”. Exp Dermatol. 2010; 19: 473-482.

  38. Francis S, Berg D. “Reducing skin malignancy risk in organ trasplant recipients”. Skin Therapy Lett. 2013; 18: 1-3.

  39. Euvrard S, Kanitakis J, Pouteil-Noble C, Dureau G, Touraine JL, Faure M, et al. “Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart trasplantation”. J Am Acad Dermatol. 1995; 33: 222-229.

  40. Buitrago-Pérez Á, Hachimi M, Dueñas M, Lloveras B, Santos A, Holguín A, et al. “A humanized mouse model of HPV-associated pathology driven by E7 expression”. PLoS One. 2012; 7: e41743.

  41. Colegio OR, Billingsley EM. “Skin cancer in trasplant recipients, out of the oods. Scientific retreat of the ITSCC and SCOPE”. Am J Trasplant. 2011; 11: 1584-1591.

  42. Perrett CM, Harwood CA, McGregor JM, Karran P. “Carcinogenic mechanisms related to immunosuppressive therapy”. Cancer Treat Res. 2009; 146: 123-132.

  43. Kelly GE, Meikle W, Sheil AG. “Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice”. Trasplantation. 1987; 44: 429-434.

  44. Otley CC, Coldiron BM, Stasko T, Goldman GD. “Decreased skin cancer after cessation of therapy with trasplant-associated immunosuppressants”. Arch Dermatol. 2001; 137: 459–463

  45. Euvrard S, Claudy A. “Post-trasplant skin cancer: the influence of organ and pre-trasplant disease”. Cancer Treat Res. 2009; 146: 65-74.

  46. Herman S, Rogers HD, Ratner D. “Immunosuppression and squamous cell carcinoma: a focus on solid organ trasplant recipients”. Skinmed. 2007; 6: 234-238.

  47. Zwald FO, Brown M. “Skin cancer in solid organ trasplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ trasplant recipients”. J Am Acad Dermatol. 2011; 65: 263-279.

  48. Veness MJ, Harris D. “Role of radiotherapy in the management of organ trasplant recipients diagnosed with non-melanoma skin cancers”. Australas Radiol. 2007; 51: 12-20.

  49. Zwald, FO, Christenson, LJ, Billingsley EM, Zeitouni NC, Ratner D, Bordeaux, J, et al. “Melanoma in Solid Organ Trasplant Recipients”. Am J of Trasplant. 2010 10: 1297–1304.

  50. Crowson AN, Magro CM, Mihm MC. “Prognosticators of melanoma, the melanoma report, and the sentinel lymph node”. Mod Pathol. 2006; 19 (suppl 2): S71-87

  51. García E, García V, Massare E, Esquivias J. “Presentación cutánea anetodérmica de un trastorno linfoproliferativo postrasplante” Actas Dermo-Sifiliográficas. 2003; 94: 243-246.

  52. Geusau A, Pohanka E. “Aftercare--a multi-disciplinary approach. Cancer Treat Res”. 2009; 146: 405-415.

  53. Cowen EW, Billingsley EM. “Awareness of skin cancer by kidney trasplant patients”. J Am Acad Dermatol. 1999; 40: 697-701.

  54. Seukeran DC, Newstead CG, Cunliffe WJ. “The compliance of renal trasplant recipients with advice about sun protection measures”. Br J Dermatol. 1998; 138: 301-303.

  55. Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, et al. “Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)”. Cancer. 2012; 118: 2128-2137.

  56. Bavinck JN, Tieben LM, Van der Woude FJ, Tegzess AM, Hermans J, ter Schegget J, et al. “Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal trasplant recipients: a double-blind, placebo-controlled study”. J Clin Oncol. 1995; 13: 1933-1938.

  57. Otley CC, Berg D, Ulrich C, Stasko T, Murphy GM, Salasche SJ et al. “Reduction of immunosuppression for trasplant-associated skin cancer: expert consensus survey”. Br J Dermatol. 2006; 154: 395-400.

  58. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. “Incidence and clinical course of de-novo malignancies in renal allograft recipients”. Eur J Surg Oncol. 2001; 27: 409-413.

  59. Martinez JC, Otley CC. “Megasession: excision of numerous skin cancers in a single session”. Dermatol Surg. 2005; 31: 757-761.




2020     |     www.medigraphic.com